#USA #San Francisco #Nektar Therapeutics #Rezpegaldesleukin #ACAAI

Nektar Therapeutics Presents New Findings on Rezpegaldesleukin

At the recent ACAAI 2025 Annual Scientific Meeting, Nektar Therapeutics shared promising results from its ongoing REZOLVE-AD Phase 2b study, focusing on its investigational drug, Rezpegaldesleukin. This first-in-class IL-2 pathway agonist demonstrated statistically significant improvements in asthma control among patients suffering from atopic dermatitis, particularly those with a history of asthma.

Study Overview

The REZOLVE-AD trial enrolled 393 patients with moderate-to-severe atopic dermatitis, of which 99 also had asthma. After 16 weeks of treatment, key findings from the Asthma Control Questionnaire (ACQ-5) showed that patients receiving Rezpegaldesleukin experienced a marked reduction in their asthma symptoms compared to those on placebo. Specifically, for doses of 24 µg/kg administered every two weeks and every four weeks, significant improvements were observed (p<0.05) in ACQ-5 scores.

Asthma Symptom Reduction Insights

The study revealed that approximately 50% of patients with at least partially controlled asthma at baseline experienced clinically significant improvement (a reduction of ≥0.5 points on ACQ-5). In stark contrast, only 13% in the placebo group demonstrated similar improvements. Moreover, among patients identified with uncontrolled asthma, all active doses of Rezpegaldesleukin markedly improved their ACQ-5 scores, with reductions ranging up to 1.4 points.

This suggests a robust potential for Rezpegaldesleukin to positively influence not just atopic dermatitis management but also asthma control, which is critical given the overlap in these conditions.

Broad Implications of the Findings

Dr. Jonathan Corren, the lead investigator from the University of California, Los Angeles, highlighted the importance of these findings. Given that nearly 25% of atopic dermatitis patients also suffer from asthma, the observed efficacy of Rezpegaldesleukin in alleviating asthma symptoms alongside improving skin conditions establishes a dual therapeutic advantage. Dr. Corren's remarks emphasize the potential for further studies to explore the drug's benefits across other T-cell mediated inflammatory diseases.

Long-term Study Plans

Nektar Therapeutics plans to advance the treatment into Phase 3 studies, emphasizing a 24-week induction period based on solid efficacy endpoints achieved during this study. By Q1 2026, more comprehensive data from the maintenance phase of the REZOLVE-AD study will be available, expected to underscore the sustainable benefits of Rezpegaldesleukin.

Conclusion

The findings presented at ACAAI not only reinforce Rezpegaldesleukin's potential as an innovative treatment option for atopic dermatitis but also open avenues for addressing asthma in patients suffering from this overlapping condition. As Nektar Therapeutics continues its clinical journey, the anticipated updates will provide further insights into this promising therapeutic approach.

For additional information on the REZOLVE-AD study and the detailed presentation, visit Nektar's official website.